Meeder Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $29.3K | Buy |
366
+233
| +175% | +$19.2K | ﹤0.01% | 509 |
|
|
2025
Q4 | $11.3K | Sell |
133
-3
| -2% | -$246 | ﹤0.01% | 636 |
|
|
2025
Q3 | $10.6K | Buy |
136
+7
| +5% | +$547 | ﹤0.01% | 540 |
|
|
2025
Q2 | $10.1K | Buy |
129
+13
| +11% | +$970 | ﹤0.01% | 614 |
|
|
2025
Q1 | $8.41K | Sell |
116
-61
| -34% | -$4.37K | ﹤0.01% | 678 |
|
|
2024
Q4 | $13.1K | Sell |
177
-16
| -8% | -$1.12K | ﹤0.01% | 641 |
|
|
2024
Q3 | $12.7K | Buy |
193
+17
| +10% | +$1.24K | ﹤0.01% | 576 |
|
|
2024
Q2 | $16.3K | Buy |
176
+22
| +14% | +$1.95K | ﹤0.01% | 559 |
|
|
2024
Q1 | $14.7K | Buy |
+154
| New | +$12.9K | ﹤0.01% | 497 |
|
|
2023
Q2 | – | Sell |
-3
| Closed | -$248 | – | 532 |
|
|
2023
Q1 | $248 | Hold |
3
| – | – | ﹤0.01% | 576 |
|
|
2022
Q4 | $224 | Sell |
3
-10,852
| -100% | -$836K | ﹤0.01% | 770 |
|
|
2022
Q3 | $897K | Buy |
10,855
+113
| +1% | +$10.9K | 0.05% | 270 |
|
|
2022
Q2 | $1.02M | Sell |
10,742
-70
| -0.6% | -$7.25K | 0.06% | 245 |
|
|
2022
Q1 | $1.27M | Buy |
+10,812
| New | +$1.21M | 0.06% | 222 |
|
|
2021
Q4 | – | Sell |
-6,874
| Closed | -$778K | – | 1545 |
|
|
2021
Q3 | $778K | Buy |
6,874
+771
| +13% | +$88K | 0.04% | 317 |
|
|
2021
Q2 | $632K | Sell |
6,103
-18,166
| -75% | -$1.71M | 0.03% | 393 |
|
|
2021
Q1 | $2.03M | Buy |
24,269
+19,713
| +433% | +$1.67M | 0.1% | 167 |
|
|
2020
Q4 | $416K | Sell |
4,556
-17,375
| -79% | -$1.44M | 0.09% | 180 |
|
|
2020
Q3 | $1.75M | Sell |
21,931
-8,192
| -27% | -$639K | 0.11% | 152 |
|
|
2020
Q2 | $2.08M | Buy |
30,123
+21,150
| +236% | +$1.5M | 0.14% | 133 |
|
|
2020
Q1 | $563K | Buy |
8,973
+1,071
| +14% | +$77.2K | 0.04% | 308 |
|
|
2019
Q4 | $614K | Buy |
7,902
+4,857
| +160% | +$379K | 0.04% | 370 |
|
|
2019
Q3 | $223K | Sell |
3,045
-60
| -2% | -$4.21K | 0.01% | 579 |
|
|
2019
Q2 | $191K | Buy |
3,105
+1,026
| +49% | +$62K | 0.01% | 594 |
|
|
2019
Q1 | $133K | Buy |
2,079
+1,218
| +141% | +$69.5K | 0.01% | 632 |
|
|
2018
Q4 | $44K | Sell |
861
-3,480
| -80% | -$176K | ﹤0.01% | 842 |
|
|
2018
Q3 | $252K | Sell |
4,341
-1,740
| -29% | -$85.1K | 0.02% | 472 |
|
|
2018
Q2 | $295K | Buy |
6,081
+3,540
| +139% | +$165K | 0.03% | 448 |
|
|
2018
Q1 | $118K | Buy |
2,541
+75
| +3% | +$3.26K | 0.01% | 522 |
|
|
2017
Q4 | $93K | Sell |
2,466
-3,744
| -60% | -$137K | 0.01% | 575 |
|
|
2017
Q3 | $226K | Buy |
6,210
+6,012
| +3,036% | +$229K | 0.02% | 450 |
|
|
2017
Q2 | $8K | Hold |
198
| – | – | ﹤0.01% | 1054 |
|
|
2017
Q1 | $6K | Sell |
198
-648
| -77% | -$20.3K | ﹤0.01% | 1000 |
|
|
2016
Q4 | $26K | Sell |
846
-56,286
| -99% | -$1.82M | ﹤0.01% | 620 |
|
|
2016
Q3 | $2.3M | Buy |
57,132
+5,703
| +11% | +$215K | 0.19% | 107 |
|
|
2016
Q2 | $1.71M | Sell |
51,429
-11,760
| -19% | -$402K | 0.16% | 131 |
|
|
2016
Q1 | $1.86M | Sell |
63,189
-37,284
| -37% | -$1.03M | 0.17% | 123 |
|
|
2015
Q4 | $2.65M | Sell |
100,473
-14,103
| -12% | -$366K | 0.24% | 118 |
|
|
2015
Q3 | $2.71M | Buy |
114,576
+89,496
| +357% | +$2.16M | 0.27% | 105 |
|
|
2015
Q2 | $595K | Sell |
25,080
-5,790
| -19% | -$131K | 0.06% | 310 |
|
|
2015
Q1 | $734K | Sell |
30,870
-52,164
| -63% | -$1.17M | 0.08% | 270 |
|
|
2014
Q4 | $1.76M | Buy |
83,034
+34,194
| +70% | +$687K | 0.22% | 137 |
|
|
2014
Q3 | $831K | Sell |
48,840
-348
| -0.7% | -$5.49K | 0.12% | 148 |
|
|
2014
Q2 | $703K | Buy |
49,188
+4,290
| +10% | +$58.2K | 0.1% | 140 |
|
|
2014
Q1 | $555K | Buy |
+44,898
| New | +$518K | 0.09% | 158 |
|
Other funds holding EW
VCM
VPM
Meeder Asset Management's EW Position: Q1 2026 in Review
Meeder Asset Management increased its Edwards Lifesciences (EW) stake by 175% in Q1 2026, buying an estimated $19.2K and bringing the position to 366 shares worth $29.3K. The position accounts for ﹤0.01% of the portfolio, ranked #509.
Meeder Asset Management first reported a position in EW in Q1 2014 and has held it in 45 quarters since. The position peaked at $2.71M in Q3 2015. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Meeder Asset Management held 366 shares of Edwards Lifesciences worth $29.3K as of Q1 2026.
- Meeder Asset Management bought 233 Edwards Lifesciences shares in Q1 2026, an estimated $19.2K.
- Edwards Lifesciences made up ﹤0.01% of Meeder Asset Management's portfolio in Q1 2026, its #509 holding.
- Meeder Asset Management first reported a position in Edwards Lifesciences in Q1 2014 and has held it in 45 quarters since.
- Meeder Asset Management's Edwards Lifesciences position peaked at $2.71M in Q3 2015.
- 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.